Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Ladenburg Thalmann 2017 Healthcare Conference
33 slides from Microbot Medical's conference presentation, Sep 26, 2017
Slide 1: Microbot Medical - Ladenburg Thalmann 2017 Healthcare Conference
microbot medical LADENBURG " THALMANN 2017 HEALTHCARE Conrerence SEPTEMBER 26, 2017 SOFITEL HOTEL + NEW YORK CITY TT > An 7 M4 aes
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. (MICROBOT’) AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided personally to you. By accepting this
Slide 3: Transforming Medical Treatments Through Micro-Invasive Robotics
TRANSFORMING MEDICAL TREATMENTS THROUGH MICRO-INVASIVE ROBOTICS Harel Gadot Chief Executive Officer, President, and Chairman NASDAQ:MBOT
Slide 4: The Initial Spark...
THE INITIAL SPARK... microbot medical
Slide 5: Evolution of Surgery...
EVOLUTION OF SURGERY... ...and the revolution of robotics in healthcare Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery Tomorrow Micro-robotics
Slide 6: Micro-Robotics Applications
MICRO-ROBOTICS APPLICATIONS micr ot medical | mo | Drug Delivery Marking Sensing Electrodes Brachytherapy | = / Biomedical micro-robotics / ae ll Stem Cells Ablation Scaffolding ‘Annual review of BioMed, Mieroxabots for MIS, 2010,
Slide 7: The Next Big-Small Thing
THE NEXT BIG-SMALL THING microbot @ Minimally Invasive Surgery (MIS) is one of the largest trends in surgical healthcare @ Global market for MIS devices in 2012 was valued at USD $25.03 Billion and is expected to reach a market value of USD $50.60 Billion by 2019. The MIS market is expected to grow
Slide 8: Solid Execution of Milestones
SOLID EXECUTION OF MILESTONES microbot Since becoming a public company nine months ago, Microbot Medical has already executed on a number of objectives within the stated timeline: @ Initiated the pre-clinical studies of first product, the Self-Cleaning Shunt @ Strengthened assets through expanded IP
Slide 9: Our Mission
micro ot OUR MISSION Enable physicians to transform medical treatments and improve patient efficacy through our micro-invasive robotic platforms
Slide 10: Investment Considerations
INVESTMENT CONSIDERATIONS microbot Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months Proven leadership t
Slide 11: Technology Platforms
TECHNOLOGY PLATFORMS ViRob @ Autonomous Advancing Micro-Robot (AAMR) @ ViRob demonstrates the ability to advance within cavities similar to the typical human body's lumens. TipCAT ®@ TipCAT is a disposable, flexible, self-propelled, — see & treat endoscope/catheter
Slide 12: Platform Technologies
PLATFORM TECHNOLOGIES micropot eS PLATFORMS SUB-PLATFORMS, o z Q iS < 9 =I = a <
Slide 13: Slide 13
Slide 14: VP Shunt Market Opportunity
VP SHUNT MARKET OPPORTUNITY @ Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. @ Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone’? @ Over 1,000,0
Slide 15: Current Shunt Technology
CURRENT SHUNT TECHNOLOGY ® Ashunt is a tube, usually silicon, which moves, or allows movement of, fluid from one part of the body to another Ventricular Catheter Shunt Valve / Distal Catheter @ Shunt products have changed little since the 1950's Ventricle Catheter CSF flow Peritoneal cavity
Slide 16: Ventricular catheter
@ Ventricular catheter @® Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated neurosurgical LN operations are often required! blockage is by far the most frequent event?
Slide 17: ViRob First Product
VIROB FIRST PRODUCT ViRob ® Self Cleaning Shunt (SCS) ® Anovel shunt technology for the continuous prevention of shunt blockage in hydrocephalus and NPH patients
Slide 18: Self Cleaning Shunt (SCS) - Lab Study
ViRob SELF CLEANING SHUNT (SCS) — LAB STUDY SCS showed the ability to prevent blockage on a shunt opening AVERAGE BLOCKAGE 100 = 90 > 80 : 2 70 eg 60 i = 50 : & 40 3 2 30 20 10 0 Scs2 Scs3 Sscs4 Ctrl 4 mscs2 mscs4 mscs3 ‘Control 1
Slide 19: Self Cleaning Shunt (SCS) - Lab Study
SELF CLEANING SHUNT (SCS) — LAB STUDY ViRob Laboratory Testing of Micro-Robotic Self-Cleaning Shunt UK Shunt Testing Lab, Cambridge University, UK CONCLUSIONS: “Microbot Medical SCS presents low hydrodynamic resistance. The SCS behaves as a standard ventricular catheter and does not change the hydro
Slide 20: TipCAT
TipCAT Leading for Life
Slide 21: TipCAT GI Endoscope Market
TipCAT GI ENDOSCOPE MARKET The North American colonoscope and upper GI endoscope segments are valued at about $600 million.’ Annually, betweene15 and 20 million endoscopy procedures areyconducted with reusable endoscope devices to screen various components of a patient’s GI tract in the USA.? a 4. N
Slide 22: Detection Rate and the GI Gap
Detection Rate: Approximately 30% of polyps are missed during Standard Colonoscopy (SC), e.g., due to polyps hidden behind colon folds and flexures.1 Leading for Life The ‘GI Gap’: Growing shortage of gastroenterologists and increasing patient volume affecting screening capacity for colorectal cance
Slide 23: Endoscope infection concerns
Leading for Life Companies’ tests used in "superbug" EcRI institute Releases Top 10 HealthTechnology RSL ON ca a v +x poo recone ‘Nighone Bacar ana Diy Sones fance Ant Want In Sleicine oor2 Rese rancor speeds don eal ges HN ‘Spey erected eh tae eng ets se, Ine 24 abuso gen ota ann Oa ans Cp cheep Pa
Slide 24: Gastrointestinal Endoscopy Procedures
Gastrointestinal Endoscopy Procedures Examining the entire colon, from the rectum to the cecum, must include the proximal colon to the splenic flexure, and it may include the terminal ileum.
Slide 25: The TipCAT colonoscope innovation
The TipCAT colonoscope innovation is driven by two proprietary concepts A Semi-disposable design: — With diagnostic and operative capabilities — Eliminate the need for cleaning / reprocessing Asimple self-propulsion mechanism — Easy operation * Allows a Physician Assistant (PA)/Nurse to perform the
Slide 26: Self-propelling through 1.3M of a pig's colon
Leading for Life SELF-PROPELLING THROUGH 1.3M (~50 INCHES) OF A PIG’S COLON
Slide 27: Organization & Infrastructure to Execute Plan
ORGANIZATION & INFRASTRUCTURE TO EXECUTE PLAN 2
Slide 28: ViRob IP Platform Family
ROB UST IP PLATFORM FAMILY ViRob US PATENT/APP NO. OTHER COUNTRIES Tip Propel Devic for Maton Through a Passage Upgne.s | Seared EP oe.eR O89, CA PCN Iifale Chamber Device forMaton Trough Passage | GSR. | Granted: EP oe rn 8m BUSS nictale Saloon Device and Applications | Ueessoete | ending: Mulivew
Slide 29: Proven Leadership Team
PROVEN LEADERSHIP TEAM ‘medical Prof. Moshe Shoham Member of the Scientific Advisory Board & Co-Founder Prof. Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 20 years, with a special focus on kinematics and dynamics of ro
Slide 30: Proven Leadership Team
PROVEN LEADERSHIP TEAM ‘medical David Ben Naim CFO Mr. Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial ® Previously served as CFO of Insuline Medical Ltd, public company listed on the Tel-Aviv Stock Exchange (TASE:INSL), ® Pri
Slide 31: Near-Term Catalysts
NEAR-TERM CATALYSTS microbot @ Completing the Self Cleaning Shunt studies at Washington University (St. Louis) and Wayne State University (Detroit). — Presenting initial data at the International Society for Hydrocephalus and Cerebrospinal Fluid Disorders annual meeting, which is being held in Kobe,
Slide 32: Investment Considerations
INVESTMENT CONSIDERATIONS microbot Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months Proven leadership t
Slide 33: Your Questions
microbot medical YOUR QUESTIONS: Michael Polyviou EVC Group mpolyviou@evcgroup.com
Microbot Medical — Ladenburg Thalmann 2017 Healthcare Conference on 6ix